ArticleThe Journal of allergy and clinical immunology2026
Beyond type 2 inflammation: An innate-myeloid axis is linked to recurrence of chronic rhinosinusitis with nasal polyps.
Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with variable outcomes after functional endoscopic sinus surgery (FESS). Predictive biomarkers for post-FESS CRSwNP recurrence remain poorly defined.
objectiveWe sought to identify tissue-based predictors of CRSwNP recurrence after FESS and assess dupilumab-induced modifications.
methodsFrom a cohort of patients with CRSwNP (including nonsteroidal anti-inflammatory drug-exacerbated respiratory disease) who underwent FESS, we retrospectively identified 91 who could be dichotomized by clinical outcome as post-FESS rapid recurrence (<1 year) or slow/no recurrence (>2 years without recurrence). Nasal polyp tissue was analyzed for 69 inflammatory mediators via proteomics and ELISA. Logistic regression with least absolute shrinkage and selection operator (aka LASSO) feature selection identified candidate predictors. In an independent, second prospective cohort of 17 CRSwNP patients initiating dupilumab, nasal fluid was collected at baseline and after 2 months of dupilumab therapy and profiled for the same mediators.
resultsTwenty-three tissue mediators strongly predicted rapid CRSwNP recurrence (area under the curve > 0.70), including markers of type 2 (T2) inflammation (IL-4, IL-13, IL-5Rα, eosinophil cationic protein, IgE) and innate inflammation and/or myeloid involvement (CCL3/4/7/8/13, CSF2, IL-1β, IL-6, oncostatin M, MMP12, HIF-1α, TNF-α, TNFSF14). Of these, dupilumab significantly reduced IL-5Rα and several chemokines (CCL3, CCL4, CCL13) but had no effect on key myeloid mediators (CCL8, CSF2, IL-1β, MMP12, HIF-1α).
conclusionsBoth T2 and non-T2 mediators play a role in rapid post-FESS recurrence in CRSwNP. T2 blockade with dupilumab reduces T2-associated mediators but does not suppress a parallel innate/myeloid inflammatory axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.